KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the sale, the chief executive officer now owns 287,811 shares in the company, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
KalVista Pharmaceuticals Stock Up 0.6 %
Shares of KALV opened at $11.99 on Tuesday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The firm has a market capitalization of $592.52 million, a PE ratio of -3.29 and a beta of 0.76. The stock's fifty day simple moving average is $9.38 and its 200-day simple moving average is $10.28.
Hedge Funds Weigh In On KalVista Pharmaceuticals
Large investors have recently made changes to their positions in the company. Aquatic Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at $44,000. Tower Research Capital LLC TRC lifted its stake in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares during the period. Legal & General Group Plc lifted its stake in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares during the period. Martin Worley Group acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares during the period.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, TD Cowen assumed coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $23.80.
Check Out Our Latest Analysis on KALV
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
